Moderna shares: Price analysis before buying or selling

Can I receive dividends when I buy Moderna shares?

No

ISIN code: US60770K1079

Ticker: NASDAQ: MRNA

Index or market: Nasdaq

How to buy and sell Moderna shares with eToro?

Open an account by clicking here

Deposit Funds

Search Moderna (NASDAQ: MRNA)

Buy/Sell Moderna shares

Your capital is at risk

Elements to consider before selling or buying Moderna shares

Analysis N°1

First, closely monitor all of Moderna's ongoing clinical trials of future vaccines or treatments, the results of which can have a very significant influence on the trend and volatility of its share.

Analysis N°2

We'll also be following the approvals of marketing authorization by international health authorities for products developed by the group.

Analysis N°3

It goes without saying that you should also take into account the particularly aggressive competition in this sector of activity by following the evolution of companies developing similar treatments.

Analysis N°4

You should also keep an eye on the company's financing through fundraising or by other companies which allow it to carry out various studies and research programs.

Analysis N°5

Finally, following the current and future financial results of this group is important, taking into account analysts' forecasts and the group's objectives.

Analysis before buying or selling Moderna shares

Buy Moderna shares

Sell Moderna shares

Your capital is at risk

General presentation of Moderna

Here, you can check out the Moderna Company and its main activities, in order to better understand how its economic environment is likely to impact its development on the stock market.

The Moderna Therapeutics group is an American company specializing in the biotechnology sector. More specifically, the company is invested in transformative medicines based on messenger RNA or mRNA. The company has even created a platform to improve the underlying pharmaceutical properties of mRNA-based drugs.

The platform focuses on three main areas:

mRNA Technology
Administration technologies
Production Process

The group is pursuing mRNA science in order to reduce unwanted activation of the immune system by mRNA and promote the potency of mRNA once in target cells. The company is also pushing forward a development pipeline of 21 different programs, 10 of which are currently in clinical studies and three have open INDs.

Among the vaccine and therapy development programs are solutions for infectious diseases, oncology, cardiovascular disease and rare genetic diseases. They are broken down into six different methods with prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, local regenerative therapies, secreted systemic therapies and intracellular systemic therapies.

An important element to mention is that Moderna is currently in the process of developing a vaccine against Covid-19.

The group employs 830 people, mainly in the United States.

Photo credits: ©grejak/123RF.COM

The major competitors of Moderna

Moderna faces rather small competition but relatively aggressive from other biotechnology companies which are developing in the same segments. Here are the main ones.

CureVac

this bio-pharmaceutical company based in Germany specializes in the development of mRNA based therapies. It particularly focuses on the development of vaccines against infectious diseases as well as drugs against cancer and rare diseases. The business currently employs 375 people.

Translate Bio Inc

This other American company also specializes in mRNA-based therapy. It develops drugs for the treatment of diseases caused by protein or genetic dysfunction. It runs its own therapeutic mRNA platform and creates an mRNA that codes for functional proteins.

BioNTech

Finally, the German company BioNTech which specializes in patient specific immunotherapies for cancer treatment and other serious diseases. This company develops products using various scientific approaches and technological platforms, including individualized product candidates based on mRNA, chimeric antigen receptor T cells, immunomodulators, antibodies targeted against cancer and small molecules.

The major partners of Moderna

Now let's check out some examples of partnerships recently signed by Moderna Therapeutics with other companies and which have had an influence on this value.

Vertex Pharmaceuticals

In 2019, Moderna signed an agreement worth over $ 300 million with Vertex to develop therapies based on messenger ribonucleic acid or mRNA for the treatment of cystic fibrosis.

Merck

In 2019, the Moderna group had already signed an important strategic partnership with the Merck group. This partnership, totalling $ 200 million plus an additional payment, the amount of which has not been revealed on human proof of concept data as part of an agreement to create personalized cancer vaccines based on mRNA.

Trade the Moderna share!

Your capital is at risk. Performance is not a guide to future performance and is not constant over time.

The factors in favour of a rise in the Moderna share price:

In order to be able to anticipate future trends in Moderna's share price in the best possible way, it is necessary to know what the company's current strengths and weaknesses are. We therefore offer you a quick analysis of these elements to help you understand its major advantages and disadvantages.
Let's start by looking at the different advantages of this stock and the strengths of this company with the strengths of this stock and its assets:

The Moderna Group has demonstrated its ability to be responsive and to quickly gain market share in the antiviral vaccine race. It was one of the first to develop a messenger RNA vaccine with Pfizer, and thus gained many points on the stock market.
But beyond this pandemic, the group's executives also explained that their technology could be used to develop cures for other respiratory infectious diseases and conditions, including respiratory syncytial virus (RSV) and cytomegalovirus (CMV), as well as other potential therapies for conditions such as cancers and inflammatory diseases.
The Moderna group's financial results also recently exceeded analysts' expectations on Wall Street, thanks in part to its sales of Covid-19 vaccines during the year. The group has also already signed multi-billion dollar advance purchase agreements for the coming year, which provides good visibility.
The consensus of analysts also remains very favourable to a future rise in this stock, with a majority of buy recommendations and another significant proportion with a neutral recommendation.
It should also be noted that the barriers to entry in Moderna's industry are high, which means that it faces little competition.
Currently, several experimental vaccines developed by the group are still in the early stages of human clinical trials, apart from the cytomegalovirus vaccine. It should be remembered that if this vaccine is validated, it could bring in several billion dollars for the company. Moderna is planning new human trials this year for a vaccine against the Epstein-Barr virus, which causes mononucleosis.
Finally, another undeniable advantage of Moderna's share price is that it is relatively easy to analyse in view of the extensive media coverage it receives. Indeed, the group has been in the headlines for several months and many analysts and investors are interested in it.

The factors in favour of a drop in the Moderna share price:

Of course, the Moderna group does not only have advantages and strengths, but also some weaknesses. We will now look at the main weaknesses of this stock.

Firstly, it should be remembered that Moderna is one of the most popular stocks on the NASDAQ this year, but it is gradually losing its appeal. The shares are currently under pressure and many analysts believe that the resumption of vaccine production has already gone too far.
The group's shares, which peaked at $493.76 in August 2021, have recently lost more than 20% of their value in a few weeks. Its stock market valuation has therefore also been revised downwards, which hampers long-term investments in this stock previously considered a growth stock.
The company's business and sales are also highly dependent on the evolution of the current health crisis and on the company's ability to go beyond vaccine production and use the potential of its messenger RNA technology, on which its antiviral vaccine is based, to treat other diseases. But many analysts are pessimistic on this point, believing that the company's current recovery has already achieved its goal.
Buying the stock with an eye on future innovations may not yield the same rapid returns as the urgent need for Covid vaccines.
Another weakness of the Moderna share that hinders sales of its shares is the lack of a dividend. Thus, the group's shareholders do not receive any remuneration for their shareholding and the stock is not considered a yielding stock.
Finally, and still according to the forecasts of the analysts specialising in this stock, and if the recommendations remain buy in the short term, some analysts foresee a revision of the price objective in the longer term downwards.

The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions or a solicitation to buy or sell an asset.

Frequently Asked Questions

Is Moderna Therapeutics stock accessible from United Kingdom?

Although the Moderna Therapeutics share price is listed on the American NYSE market, it is possible to speculate on this value from United Kingdom. To do so, however, you need to refer to an online trading platform that offers the value and therefore has access to stocks of foreign companies, including American stocks. This is the case with online CFD trading platforms.

How to track the Moderna group news?

You can follow the Moderna group news by consulting data published on the company's website particularly the clinical trials and various phases of tests carried out on the treatments and vaccines under development, along with all the related news on the company including financial publications, on-going strategic operations, partnerships and other major communication.

When should you take a position on the Moderna Therapeutics share price?

If you want to trade the Moderna Therapeutics share price, the best time to buy would of course be at the beginning of an uptrend. To do so, you can base yourself on the fundamental analysis of this value and detect the events that will influence an increase in its price. During a downtrend, you should follow the technical data as well as the news which may disappoint investors and shareholders in the short term.

Trade the Moderna share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.

Analysis before buying or selling Moderna shares